Read our latest announcements
Filter by year:
Modus Therapeutics AB announced the results from an exploratory Phase I/II clinical trial in malaria with its candidate drug sevuparin.
Modus Therapeutics AB announces that Christina Herder has been appointed as its new Chief Executive Officer.
Sankt Eriksgatan 117,
SE-113 43 Stockholm, Sweden
© 2019 Modus Therapeutics. | All Rights Reserved.